Author: Florian Mueller
-
Tokyo District Court publishes SEP mediation guidelines: fundamentally incompatible with Western legal culture
In the Western hemisphere, mediation is shielded from litigation. The Tokyo District Court, however, has a different approach.
-
Munich court calls UK interim-license declarations “flawed in legitimacy”, deems UK courts incompetent to impose global licenses; finds pool rates far below FRAND
A redacted Nokia v. ASUS ruling showcases the application of the Munich court’s FRAND guidelines and takes a clear position on the illegitimacy of UK interim-license declarations.
-
EU Commission officially indicates concern over UPC-UK antisuit conflict; UPC CoA schedules InterDigital-Amazon hearing for May 28
The European Commission’s cordial letter to the Mannheim Local Division’s Presiding Judge encourages the court to share further information.
-
UK court prepared to expedite Warner Bros. Discovery, Paramount FRAND trials against Nokia to maximum extent — but will it matter?
Mr Justice Meade will take Warner Bros. Discovery’s and Paramount’s FRAND actions against Nokia to trial at the earliest opportunity, hoping to influence outcomes in other courts.
-
EU Commission study on application of IPR Enforcement Directive shows no pressing problem with patent assertion entities
The European Commission has released a report on the application of the EU’s IPR Enforcement Directive throughout the bloc. There does not appear to be a pressing need to legislate.
-
Via licensors Dolby and IP Bridge sue China’s Skyworth and three local players in Brazil: apparently AVC/H.264 patent enforcement
Skyworth is a major TV maker. The other defendants are Brazilian consumer electronics manufacturers.
-
Erich Spangenberg’s SIM IP starts FusionLayer patent enforcement with complaint against Infoblox in UPC Hamburg LD
Last spring, Erich Spangenberg’s SIM IP completed the acquisition of FusionLayer’s cloud computing, virtual networking and internet protocol address management patent portfolio.
-
Roche’s Genentech, Organon, China’s Henlius settle major pertuzumab biosimilar litigation in U.S., UPC, NL, and Brazil (where it was most advanced)
A favorable validity decision by the Brazilian patent office and evidence preservation in the UPC contributed to this important biosimilar settlement.